(MENAFNEditorial)
The World Health Organization's approval of a quality control laboratory for medicines in Zimbabwe is a positive step for the country's pharmaceutical market. It will help to reduce the proportion of counterfeit medicines in circulation and increase the country's attractiveness to multinational drugmakers. Nevertheless for the foreseeable future the dire economic and political outlook reduced healthcare budget and underdeveloped local manufacturing industry will continue to limit investment.
Headline Expenditure Projections
* Pharmaceuticals: USD378mn in 2013 to USD388mn in 2014; +2.8% in US dollar terms. Forecast revised up from last quarter's projections to better suit current market conditions.
Full Report Details at
- http://www.fastmr.com/prod/924327_zimbabwe_pharmaceuticals_healthcare_report_q1.aspx?afid=101
Risk/Reward Index
In BMI's RRI table for Q1 2015 Zimbabwe scores 29 out of 100 unchanged from the previous quarter. The country ranks 29th out of the 31 markets assessed in the Middle East and Africa (MEA) region.
Key Trends And Developments
November 2014
* Patients are increasingly going to private medical institutions to receive medical attention due to a strike by doctors in public hospitals across Zimbabwe reports allAfrica. The few available doctors at public hospitals in the country are only attending to emergency cases being brought to hospitals. There is less activity going on at government hospitals compared with operations being carried out at private medical institutions according to a study by The Herald. Patients at medical institutions such as Avenues Clinic Baines 24 Hour and West End have stated in separate interviews that they had to visit private institutions as they could not get help at public hospitals.
* Under a private-public partnership initiative more than 400 pharmacies in Zimbabwe have been authorised to sell anti-retrovirals (ARVs). The move has reduced the average cost of treatment at pharmacies by more than 50%. Under the new arrangements the National AIDS Council (NAC) sources ARVs in bulk and distributes them...
The Zimbabwe Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Zimbabwe Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Zimbabwean pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Zimbabwe to test other views - a key input for successful budgeting and strategic business planning in the Zimbabwean pharmaceutical and healthcare market.
* Target business opportunities and risks in the Zimbabwean pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Zimbabwe.
* Assess the activities strategy and market position of your competitors partners and clients via our Company Profiles (inc. SWOTs KPIs and latest activity) and Competitive Landscape Tables.
Coverage
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis and taken together with BMI's political economic and business environment SWOTS it gives a complete overview of market climate.
Market Summary
Snapshot of key market characteristics including total size of pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape.
Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as an analysis of the overall regulatory burden.
Industry Developments
Focus on government healthcare reforms epidemiological trends company M&As product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions plus analysis of key downside risks to the main forecast including:
Healthcare: Total healthcare expenditure (US$bn) healthcare expenditure (% of GDP) healthcare expenditure per capita (US$) hospital beds (per `000 population) doctors (per `000 population) birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn) drug expenditure (% of GDP) drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn) prescription sales (% of total sales) sales broken down by 14 therapeutic areas (cardiovascular anti-infectives etc.)
Generic drug market: Generic product sales (US$bn) generic sales (% of total sales)
OTC drug market: OTC sales (US$bn) OTC sales (% of total sales) sales broken down by product types (analgesics skin treatments vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn) medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against US$ government expenditure external debt.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.